FIELD: biotechnology.
SUBSTANCE: invention relates to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), where CAR contains a CD20-binding domain, a transmembrane domain and an intracellular signaling domain, an isolated polypeptide molecule for binding to CD20, as well as to CD20- linking domain. A polyspecific CAR molecule is also disclosed, providing a first binding specificity for CD20 and a second binding specificity for CD22 or CD19. The invention also relates to a vector, cell and cell population containing a nucleic acid molecule encoding a CAR for binding to CD20.
EFFECT: invention is effective for the treatment of cancer.
51 cl, 30 dwg, 19 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
| TREATMENT OF MALIGNANT TUMOR USING ANTI-CD19 ANTIGEN CHIMERIC RECEPTOR | 2015 |
|
RU2815417C2 |
| CHIMERIC ANTIGEN RECEPTORS M971 | 2018 |
|
RU2770411C1 |
